BIOCOMPOSITES


Associated tags: Foot, Spine, Ankle, Podiatry, Infection, Trauma, Antibiotics, Pharmaceutical industry, Surgeon, Patient, Vancomycin, Genetically modified bacteria, Hospital, Genex Power, Research, Tobramycin, EU

Locations: UNITED KINGDOM, UNITED STATES OF AMERICA, ENGLAND, ITALY

Biocomposites expands its international presence by opening new sales and distribution office in Italy

Retrieved on: 
Tuesday, January 16, 2024

Led by Pierluigi Leone, General Manager, the sales team will continue to work with local agents to fulfil tenders and introduce the broader Biocomposites portfolio to surgeons and hospitals throughout Italy.

Key Points: 
  • Led by Pierluigi Leone, General Manager, the sales team will continue to work with local agents to fulfil tenders and introduce the broader Biocomposites portfolio to surgeons and hospitals throughout Italy.
  • Pierluigi Leone, Amministratore delegato e General Manager of Biocomposites Italy, commented: "This is an exciting time for Biocomposites Italy.
  • We have established an experienced team, incorporated Biocomposites SRL, and set up our new distribution centre in only a few months.
  • We formally opened the office at the beginning of the year and are already providing surgeons with our unique products.

Biocomposites expands its international presence by opening new sales and distribution office in Italy

Retrieved on: 
Tuesday, January 16, 2024

Led by Pierluigi Leone, General Manager, the sales team will continue to work with local agents to fulfil tenders and introduce the broader Biocomposites portfolio to surgeons and hospitals throughout Italy.

Key Points: 
  • Led by Pierluigi Leone, General Manager, the sales team will continue to work with local agents to fulfil tenders and introduce the broader Biocomposites portfolio to surgeons and hospitals throughout Italy.
  • Pierluigi Leone, Amministratore delegato e General Manager of Biocomposites Italy, commented: "This is an exciting time for Biocomposites Italy.
  • We have established an experienced team, incorporated Biocomposites SRL, and set up our new distribution centre in only a few months.
  • We formally opened the office at the beginning of the year and are already providing surgeons with our unique products.

Biocomposites' investee Renovos Biologics receives FDA Breakthrough Device Designation for its synthetic nanoclay bone fusion gel, RENOVITE® BMP-2

Retrieved on: 
Thursday, January 4, 2024

RENOVITE® BMP-2, based on a proprietary synthetic nanoclay gel, is in development as a safer and more effective alternative to currently available bone graft materials.

Key Points: 
  • RENOVITE® BMP-2, based on a proprietary synthetic nanoclay gel, is in development as a safer and more effective alternative to currently available bone graft materials.
  • The nanoclay gel enables safe, highly-targeted bone fusion, as it does not leach BMP-2, with the gel biodegrading as new bone forms.
  • Dr Agnieszka Janeczek, Chief Executive Officer of Renovos Biologics, said: "We are very pleased with the Breakthrough Device Designation from the FDA, being among just one hundred or so companies granted this designation in orthopaedics since the programme's launch in 2015.
  • The designation will allow Renovos to have more frequent interaction with the FDA's regulatory experts when preparing its submissions, followed by prioritised reviews.

Biocomposites' investee Renovos Biologics receives FDA Breakthrough Device Designation for its synthetic nanoclay bone fusion gel, RENOVITE® BMP-2

Retrieved on: 
Thursday, January 4, 2024

RENOVITE® BMP-2, based on a proprietary synthetic nanoclay gel, is in development as a safer and more effective alternative to currently available bone graft materials.

Key Points: 
  • RENOVITE® BMP-2, based on a proprietary synthetic nanoclay gel, is in development as a safer and more effective alternative to currently available bone graft materials.
  • The nanoclay gel enables safe, highly-targeted bone fusion, as it does not leach BMP-2, with the gel biodegrading as new bone forms.
  • Dr Agnieszka Janeczek, Chief Executive Officer of Renovos Biologics, said: "We are very pleased with the Breakthrough Device Designation from the FDA, being among just one hundred or so companies granted this designation in orthopaedics since the programme's launch in 2015.
  • The designation will allow Renovos to have more frequent interaction with the FDA's regulatory experts when preparing its submissions, followed by prioritised reviews.

Biocomposites expands its product portfolio with the launch of SYNICEM™ spacers in the UK

Retrieved on: 
Tuesday, November 21, 2023

SYNICEMTM hip, knee and shoulder spacers are preformed and loaded with gentamicin to maintain space and aid treatment of infection.

Key Points: 
  • SYNICEMTM hip, knee and shoulder spacers are preformed and loaded with gentamicin to maintain space and aid treatment of infection.
  • SYNICEMTM spacers are antibiotic-loaded, preformed spacers which overcome the challenges of traditional intra-operative moulded and handmade spacers.
  • The launch of SYNICEMTM spacers in the UK follows Biocomposites' acquisition of French-based medical device manufacturer, Synimed, in 2022.
  • SYNICEM spacers already help many patients throughout the world and bringing them into the UK and wider Biocomposites network will ensure that more patients benefit."

Biocomposites expands its product portfolio with the launch of SYNICEM™ spacers in the UK

Retrieved on: 
Tuesday, November 21, 2023

SYNICEMTM hip, knee and shoulder spacers are preformed and loaded with gentamicin to maintain space and aid treatment of infection.

Key Points: 
  • SYNICEMTM hip, knee and shoulder spacers are preformed and loaded with gentamicin to maintain space and aid treatment of infection.
  • SYNICEMTM spacers are antibiotic-loaded, preformed spacers which overcome the challenges of traditional intra-operative moulded and handmade spacers.
  • The launch of SYNICEMTM spacers in the UK follows Biocomposites' acquisition of French-based medical device manufacturer, Synimed, in 2022.
  • SYNICEM spacers already help many patients throughout the world and bringing them into the UK and wider Biocomposites network will ensure that more patients benefit."

Biocomposites to host a symposium and present new STIMULAN® data at the European Bone and Joint Infection Society Annual Meeting

Retrieved on: 
Thursday, October 5, 2023

Findings from the study demonstrate the efficacy of STIMULAN® beads, when combined with vancomycin and gentamicin, in combating antibiotic tolerant biofilm-like aggregates.

Key Points: 
  • Findings from the study demonstrate the efficacy of STIMULAN® beads, when combined with vancomycin and gentamicin, in combating antibiotic tolerant biofilm-like aggregates.
  • Dr. Yvonne Achermann and I look forward to speaking on the merits of local antibiotic delivery in managing infection at this upcoming industry meeting."
  • Michael Harris, Chief Executive Officer of Biocomposites, added: "EBJIS is an important annual event at which surgeons, podiatrists and scientists catch up on the latest information in the field of bone and joint infection treatment.
  • Details of Biocomposites' symposium and the abstract accepted at the EBJIS Annual Meeting are listed below:
    Presenters: Mr.

Biocomposites to host a symposium and present new STIMULAN® data at the European Bone and Joint Infection Society Annual Meeting

Retrieved on: 
Thursday, October 5, 2023

Findings from the study demonstrate the efficacy of STIMULAN® beads, when combined with vancomycin and gentamicin, in combating antibiotic tolerant biofilm-like aggregates.

Key Points: 
  • Findings from the study demonstrate the efficacy of STIMULAN® beads, when combined with vancomycin and gentamicin, in combating antibiotic tolerant biofilm-like aggregates.
  • Dr. Yvonne Achermann and I look forward to speaking on the merits of local antibiotic delivery in managing infection at this upcoming industry meeting."
  • Michael Harris, Chief Executive Officer of Biocomposites, added: "EBJIS is an important annual event at which surgeons, podiatrists and scientists catch up on the latest information in the field of bone and joint infection treatment.
  • Details of Biocomposites' symposium and the abstract accepted at the EBJIS Annual Meeting are listed below:
    Presenters: Mr.

Biocomposites appoints two new Directors to strengthen its team for its next phase of growth

Retrieved on: 
Wednesday, August 2, 2023

KEELE, England, Aug. 2, 2023 /PRNewswire/ -- Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, has strengthened its leadership team with the addition of two new Directors. Michelle Lewis has become Human Resources Director and Ciara Airey has become Regulatory Affairs Director. Both appointments come in response to the company's strong growth and the need to manage an increasing talent pool of people, whilst maximising the opportunity to grow revenue through regulatory differentiation.

Key Points: 
  • Michelle Lewis has become Human Resources Director and Ciara Airey has become Regulatory Affairs Director.
  • Michelle Lewis brings with her an impressive 25-year track record in senior HR positions, including board membership.
  • Her expertise spans various sectors, and she has successfully implemented strategic HR plans and managed HR operations throughout her career.
  • She has also held roles in CRO, consulting and pharma, specialising in regulatory and clinical strategy for high-risk diagnostic devices.

Biocomposites appoints two new Directors to strengthen its team for its next phase of growth

Retrieved on: 
Wednesday, August 2, 2023

KEELE, England, Aug. 2, 2023 /PRNewswire/ -- Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, has strengthened its leadership team with the addition of two new Directors. Michelle Lewis has become Human Resources Director and Ciara Airey has become Regulatory Affairs Director. Both appointments come in response to the company's strong growth and the need to manage an increasing talent pool of people, whilst maximising the opportunity to grow revenue through regulatory differentiation.

Key Points: 
  • Michelle Lewis has become Human Resources Director and Ciara Airey has become Regulatory Affairs Director.
  • Michelle Lewis brings with her an impressive 25-year track record in senior HR positions, including board membership.
  • Her expertise spans various sectors, and she has successfully implemented strategic HR plans and managed HR operations throughout her career.
  • She has also held roles in CRO, consulting and pharma, specialising in regulatory and clinical strategy for high-risk diagnostic devices.